Evolus (EOLS) Free Cash Flow Growth (1y) (2018 - 2026)
Evolus (EOLS) Free Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 84.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.69% |
| Mar 31, 2026 | 37.53% |
| Dec 31, 2025 | 177.80% |
| Sep 30, 2025 | -192.52% |
| Jun 30, 2025 | -265.76% |
| Mar 31, 2025 | -46.73% |
| Dec 31, 2024 | 561.12% |
| Sep 30, 2024 | -278.38% |
| Jun 30, 2024 | 44.43% |
| Mar 31, 2024 | 47.77% |
| Dec 31, 2023 | 106.86% |
| Sep 30, 2023 | 91.76% |
| Jun 30, 2023 | 36.21% |
| Mar 31, 2023 | 45.53% |
| Dec 31, 2022 | -13.76% |
| Sep 30, 2022 | 46.79% |
| Jun 30, 2022 | -232.08% |
| Mar 31, 2022 | -358.06% |
| Dec 31, 2021 | -287.83% |
| Sep 30, 2021 | -165.14% |